Gopten (Trandolapril)

Gopten (trandolapril) is indicated for oral use in several cardiovascular conditions where reduction of blood pressure or cardiac workload is desired.

• Treatment of essential (primary) hypertension, either alone or in combination with other antihypertensive agents.
• Management of chronic heart failure to improve symptoms and reduce hospitalization risk.
• Adjunct therapy after myocardial infarction to attenuate adverse ventricular remodeling.
• Use in patients with left ventricular dysfunction to support cardiac function.
• Consideration as part of a stepped‑care approach for blood‑pressure control when first‑line agents are insufficient.

Trandolapril, like other ACE inhibitors, can produce side effects that range from mild and transient to potentially serious. Patients should be aware of the most frequently reported reactions as well as those that require immediate medical attention.

Common

• A persistent dry cough, often described as tickling, may develop during treatment.
• Dizziness or light‑headedness, particularly after the initial dose, can occur as blood pressure falls.
• Headache of mild to moderate intensity is reported by some patients.
• Fatigue or a general feeling of weakness may be experienced, especially when therapy is started.

Serious

• Angioedema, characterized by rapid swelling of the face, lips, tongue, or airway, requires urgent care.
• A notable rise in blood urea nitrogen or serum creatinine may signal renal impairment and should be evaluated promptly.
• Elevated potassium levels (hyperkalemia) can lead to muscle weakness or cardiac rhythm disturbances and need monitoring.

Before initiating Gopten, clinicians should evaluate several patient‑specific factors to minimize risk and ensure safe use.

• Pregnancy: safety category is unknown; use only if the potential benefit justifies the potential risk to the fetus.
• Renal impairment: dose adjustment may be required and renal function should be monitored.
• Hyperkalemia: avoid concomitant use of potassium‑sparing agents without monitoring serum potassium.
• Hypotension: patients prone to low blood pressure, such as those on diuretics, should be observed closely.
• History of angioedema: avoid in patients who have previously experienced angioedema with ACE inhibitors.
• Elderly patients: start with lower doses and monitor for orthostatic hypotension.

Trandolapril may interact with other medicines, altering its effectiveness or increasing the likelihood of adverse reactions.

Avoid

• Aliskiren in patients with diabetes or renal impairment, due to increased risk of renal dysfunction.
• Potassium‑sparing diuretics or potassium supplements, which can precipitate hyperkalemia.
• Lithium, as ACE inhibition may raise lithium concentrations and cause toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may reduce antihypertensive effect and impair renal function.
• Other antihypertensive agents, especially diuretics, because combined therapy can cause excessive hypotension.
• Azathioprine, as concurrent use may increase the risk of neutropenia.